PF-Atlas › Clinical Trials › NCT06717100
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone and Nintedanib
Nintedanib 150 MG [Ofev] · Phase 1
Registry ID
NCT06717100
Phase
Phase 1
Status
Completed
Drug / intervention
Nintedanib 150 MG [Ofev]
Sponsor
PureTech
Start
2024-12-17
About this trial
Nintedanib 150 MG [Ofev] is evaluated in NCT06717100, a Phase 1 idiopathic pulmonary fibrosis study sponsored by PureTech. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06717100 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.